All News
Male vs. Female Responders (4.15.2022)
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Read Article
Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor
MedPage Today
Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.
Read Article
Is Alzheimer's Risk Lower With TNF Inhibitors?
MedPage Today
Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.
Read Article
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA
37 RCTs = 14.115 PsA pts
◾️ bDMARDs > PBO
◾️ bDMARDs = MTX (or Tofa)
◾️ bDMARDs + MTX > MTX
https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic
LFT Elevations may be considered differently in PsA patients
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Laura Coates discusses Precision Medicine in PsA.
https://t.co/ttKHZDGjyC https://t.co/XwahihZyGH
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic
Reasons why PsA patient can lose biologic efficacy and what to do about it
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Combined Clinics for PsA
Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week.
https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH
Links:
Dr. John Cush RheumNow ( View Tweet)
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF
Links:
Dr. John Cush RheumNow ( View Tweet)
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM
Links:
Dr. John Cush RheumNow ( View Tweet)
ArthritisPower study of 332 #PsA pts finds patients are most bothered by joint pain, MSK pain & fatigue. Patients prefer oral, QD meds; 3/4 want Rx that improved joints vs skin; and would prefer to avoid MTX https://t.co/WYqWgoimOT https://t.co/RgGeCKrpT1
Links:
Dr. John Cush RheumNow ( View Tweet)
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/UOPteZY0g8 https://t.co/Xw3ZSPWeE0
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/M6y5Gezhjs https://t.co/HYoI3pExRm
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:The Enthesitis Challenge in Psoriatic Arthritis
A colleague of mine told me an interesting story about how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had PsA with enthesitis all along.
Read more...
https://t.co/bSYdtlL41J https://t.co/gKKdWTvyMB
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: TNR Recap: What Patients Say About PsA
Watch Tuesday Nite Rheumatology, held on 4/5/22,which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.
PsA Panelists included:
- Tena Brown
- Christine Lindsay
- Ashley Krivohlavek
https://t.co/FyjnzrtKqp https://t.co/uEHsoAwHLY
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Dactylitis Indicates a Severe PsA Phenotype
https://t.co/7VVoc0f1Ap https://t.co/uZxfqLvtcp
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us on April 12th for Tuesday Night Rheumatology at 7pm ET.
This week will host a conversation between Dr. Cush and Dr. Artie Kavanaugh on PsA medical journal articles.
Register today: https://t.co/YQD598xt7X https://t.co/k5uDeojEh7
Links:
Dr. John Cush RheumNow ( View Tweet)
Depression was studied in 208 #PSA patients - Depression was found in 30%. Depression risk was higher in those with higher disease activity (DAPSA; P=.007) and functional impairment (HAQ-DI; p=-.02) https://t.co/0bZ2xPprTp https://t.co/Gdiic5iKCi
Links:
Dr. John Cush RheumNow ( View Tweet)
